MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
Chronic Myeloid Leukemia Treatments
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,136 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,136 works in the cohort · of 4,299,418page 6 of 23

Labels cover 0 of 1,136 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,136 of 1,136 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affunlabeled
Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs
Andreas Hochhaus, Carla Boquimpani, Delphine Réa, Yosuke Minami, Elza Lomaia, Sergey Voloshin +20 more
2020· article· en· Blood· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
26
citations
affaboutunlabeled
Clinical efficacy of generic imatinib
Mário L de Lemos, Victoria Kyritsis
2014· article· en· Journal of Oncology Pharmacy Practice· Medicine
distilled prediction:candidate · metaresearchconsensus · none
25
citations
afffundno abstractunlabeled
The Challenges of Targeting Chronic Myeloid Leukemia Stem Cells
Xiaoyan Jiang, Clayton A. Smith, Allen Eaves, Connie J. Eaves
2007· review· en· Clinical Lymphoma & Myeloma· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrity+insufficient_payloadconsensus · metaepi_narrow
24
citations
affunlabeled
Abstracts
2018· article· en· British Journal of Haematology· Medicine
distilled prediction:candidate · noneconsensus · none
23
citations
affno abstractunlabeled
STI-571 (Imatinib Mesylate) Enhances the Apoptotic Efficacy of Pyrrolo-1,5-Benzoxazepine-6, a Novel Microtubule-Targeting Agent, in Both STI-571-Sensitive and -Resistant Bcr-Abl-Positive Human Chronic Myeloid Leukemia Cells
Lisa M. Greene, Liam Kelly, Valeria Onnis, Giuseppe Campiani, Mark Lawler, D. Clive Williams +1 more
2007· article· en· Journal of Pharmacology and Experimental Therapeutics· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
22
citations
afffundunlabeled
Final report of <scp>TKI</scp> discontinuation trial with dasatinib for the second attempt of treatment‐free remission after failing the first attempt with imatinib: Treatment‐free Remission Accomplished by Dasatinib (<scp>TRAD</scp>) study
María Agustina Perusini, Igor Novitzky‐Basso, Eshetu G. Atenafu, Donna L. Forrest, Isabelle Bence‐Bruckler, Lynn Savoie +11 more
2023· article· en· British Journal of Haematology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
20
citations

How this was built: Screen · Findings · About